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The gene cluster responsible for the production of the aureocin A53-like bacteriocin,
lactolisterin BU, is located on plasmid pBU6 in Lactococcus lactis subsp. lactis BGBU1-
4. Heterologous expression of pBU6 confirmed that production and limited immunity to
lactolisterin BU were provided by the plasmid. Comparative analysis of aureocin A53-
like operons revealed that the structural genes shared a low level of identity, while other
genes were without homology, indicating a different origin. Subcloning and expression of
genes located downstream of the structural gene, lliBU, revealed that the lactolisterin BU
cluster consists of four genes: the structural gene lliBU, the abcT gene encoding an ABC
transporter, the accL gene encoding an accessory protein and the immL gene which
provides limited immunity to lactolisterin BU. Reverse transcription analysis revealed that
all genes were transcribed as one polycistronic mRNA. Attempts to split the lactolisterin
BU operon, even when both parts were under control of the PlliBU promoter, were
unsuccessful indicating that expression of lactolisterin BU is probably precisely regulated
at the translational level by translational coupling and is possible only when all genes of
the operon are in cis constellation. Two ρ-independent transcription terminators were
detected in the lactolisterin BU operon: the first in the intergenic region of the lliBU and
abcT genes and the second at the end of operon. Deletion of the second transcription
terminator did not influence production of the bacteriocin in lactococci.
Keywords: bacteriocin, lactolisterin BU operon, ABC transporter, limited immunity, translational coupling
INTRODUCTION
Ribosomal synthesis of antimicrobial peptides or peptide complexes, known as bacteriocins,
presents a successful strategy for the reduction of microbial competitors to obtain more nutrients
and living space in the environment (Cotter et al., 2013). They can be active against closely related
bacterial species or different bacterial genera, and the producer protects itself by synthesis of specific
immunity proteins (Kjos et al., 2014). Bacteriocins produced by lactic acid bacteria (LAB) are
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generally regarded as natural and suitable for consumption as
they have been present in many foods and beverages since ancient
times (Cleveland et al., 2001). Numerous studies reported that
bacteriocins may be applied in the food industry to extend food
preservation time (Cotter et al., 2005; Yang et al., 2014; Ahmad
et al., 2017). A number of studies consider potential clinical
applications of bacteriocins for maintenance of human health as
a part of anti-infection or even are able to cause apoptotic and
necrotic death of cancer cells in vitro (Lagos et al., 2009; Yang
et al., 2014; Ahmad et al., 2017; Baindara et al., 2017). In addition
to being administered as food supplements, some bacteriocins
may be produced at the site of infection by probiotic bacteria
(Gotteland et al., 2008).
Bacteriocins differ in molecular mass, structure, biochemical
and genetic characteristics, modes of action and target cell
receptors. Based on these criteria, bacteriocins from LAB are
generally classified into two main classes: Class I bacteriocins
(lantibiotics) contain unusual amino acids such as lanthionine
and dehydrated amino acids as a result of post-translational
modifications and Class II bacteriocins consisting of unmodified
or peptides with minor modifications. Furthermore, Class II
bacteriocins are subdivided into four subclasses: pediocin-
like bacteriocins (class IIa), two-peptide bacteriocins (class
IIb), cyclic bacteriocins (IIc), and linear non-pediocin-like
bacteriocins (class IId) (Cotter et al., 2013). Recently a new
modified classification of LAB bacteriocins was proposed
(Alvarez-Sieiro et al., 2016) with two main differences: (a)
the introduction of class III which includes thermo-labile
bacteriolysins and non-lytic bacteriocins with a molecular
mass greater than 10 kDa and (b) leaderless bacteriocins are
classified as subclass IIc. Class II bacteriocins, in general, are
small (37–58 amino acids) cationic peptides with pIs varying
from 8 to 11. They contain a relatively high number of
small amino acids such as glycine and alanine, giving them a
high degree of conformational freedom (Kaiser and Montville,
1996). Most bacteriocins are synthesized as a pro-peptide
with an N-terminal leader sequence, which is cleaved by a
dedicated ABC transporter or the Sec system during export
from cells. However, there is a group of so-called leaderless
bacteriocins, which are synthesized without an N-terminal
leader sequence and the mechanism behind their export is still
unknown. Leaderless bacteriocins are often relatively small (30–
50 amino acids) and without modifications (Ovchinnikov et al.,
2017).
Bacteriocin genetic systems can be located on chromosomes,
plasmids or conjugative transposons (Engelke et al., 1992; Rauch
and De Vos, 1992; De Vos et al., 1995; Kojic et al., 2005). Class
II bacteriocins are organized in operons consisting of at least
four genes: a structural gene, an immunity gene, a transporter
gene and an accessory protein gene (Nes et al., 1996; Mesa-
Pereira et al., 2017) or in gene clusters. The structural bacteriocin
gene encodes a pre-form of the bacteriocin containing an
N-terminal leader sequence (except leaderless bacteriocins). Each
bacteriocin has its own protein conferring immunity encoded
by an immunity gene located next to or close downstream of
the bacteriocin structural gene. The ABC transporter protein is
responsible for transport of the bacteriocin from the cytoplasm
to the outside of the membrane and for extracellular activation
by cleavage of the leader sequence. An additional gene encoding
an accessory protein (approximately 470 amino acids) is usually
located next to the ABC transporter and is apparently required
for the ABC-transporter-dependent translocation process (Nes
et al., 1996). Expression of bacteriocin genes is usually regulated
by external induction factors, in most cases small peptides
secreted by the producer strain itself or by its competitors for
the ecological resources. The production of class II bacteriocins is
transcriptionally regulated by a three component quorum sensing
system, which consists of an induction factor, a membrane-
associate protein histidine kinase, and response regulators (Diep
et al., 2003). Recently, it has been described for the first time that
the expression of LsbB, a leaderless bacteriocin, is regulated by
a transcription terminator sequence located downstream of the
structural gene (Uzelac et al., 2015). However, in some cases,
bacteriocin production depends on environmental conditions
such as temperature, pH and free peptide concentration.
In this study, we investigated the function of the hypothetical
genes within the lactolisterin BU gene cluster of Lactococcus
lactis subsp. lactis BGBU1-4. Previously, it was shown that strain
BGBU1-4 produces a novel, leaderless bacteriocin, lactolisterin
BU, with strong antimicrobial activity against many species
of Gram-positive bacteria, including important food spoilage
and food-borne pathogens such as Listeria monocytogenes,
Staphylococcus aureus, Bacillus sp. and streptococci. The
production of lactolisterin BU is related to the smallest plasmid
pBU6 of 6.2 kb, which contains nine open reading frames (ORFs):
repB, lliBU, abcT, hyp1, hyp2, hyp3, mobC, relM, and rnaY (Lozo
et al., 2017). An identity (BLAST) search within the lactolisterin
BU operon recognized the product of the abcT gene as a sugar
transporter, while other genes were designated as hypothetical.
The aim of this work was to determine the function of the
hypothetical genes (hyp1, hyp2, and hyp3) and their involvement
in bacteriocin activity.
MATERIALS AND METHODS
Bacterial Strains and Growth Conditions
The strains, their derivatives and plasmids used in this study are
listed in Table 1. Lactococcus lactis strains were grown in M17
medium (Merck GmbH, Darmstadt, Germany) supplemented
with 0.5% glucose (GM17) at 30◦C. Escherichia coli strains
(DH5α and EC101) were grown in Luria Bertani broth (LB)
at 37◦C with aeration. To each medium, agar (1.5%; Torlak,
Belgrade, Serbia) was added for use as a solid medium.
The following antibiotic concentrations were used: ampicillin,
100 µg/ml (E. coli); erythromycin, 10 µg/ml (lactococci) and
300 µg/ml (E. coli); chloramphenicol, 10 µg/ml (lactococci) and
35 µg/ml (E. coli). The 5-bromo-4-chloro-3-indolyl-β-D-galacto-
pyranoside (X-Gal) (Fermentas, Vilnius, Lithuania) was added to
LB medium plates for blue/white color screening of colonies with
cloned fragments at a final concentration of 80 µg/ml (lactococci)
and 40 µg/ml (E. coli). Ortho-nitrophenyl-β-galactoside (ONPG)
was used for the β-galactosidase assay (Sigma Chemical Co., St.
Louis, MO, United States).
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Lactococcus lactis subsp. lactis
BGBU1-4 Bacteriocin (lactolisterin BU) producer Golić et al., 2013
BGMN1-596 Plasmid free derivative of L. lactis subsp. lactis BGMN1-5 Gajic et al., 1999
Lactococcus lactis subsp. cremoris
MG7284 Prt−, Lac−, Bacr, Fusr, Spcr Gasson, 1983
Escherichia coli
DH5α supE44 1lacU169 (ø80 lacZ1M15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 Hanahan, 1983
EC101 JM101 containing repA gene of pWV01 in chromosome Law et al., 1995
Plasmids
pBU6 6.2 kb, natural plasmid carrying lactolisterin BU gene cluster from strain BGBU1-4 Lozo et al., 2017
pBluescriptT/A 2994 bp, Ampr , PCR cloning vector Uzelac et al., 2015
pAZIL 7,109 bp, Emr , shuttle cloning vector Kojic et al., 2011
pNZ8150 Cmr , NICE expression vector Mierau and
Kleerebezem, 2005
pNZ8150-lacZ1 pNZ8150 carrying lacZ1 gene Vukotic et al., 2015
pAZIL-SP SacI/PvuII fragment (lliBU, abcT, hyp1, hyp2, hyp3 and part of mobC) from pBU6 into pAZIL
predigested with SacI/SmaI
This work
pAZIL-SB SacI/BglII fragment (lliBU, abcT, hyp1 and hyp2) from pBU6 into pAZIL predigested with
SacI/BamHI
This work
pAZIL-SS SacI/ScaI fragment (lliBU and abcT ) from pBU6 into pAZIL predigested with SacI/SmaI This work
pAZIL-pBU6P-1 pBU6 digested with PvuII into pAZIL predigested with SmaI (first orientation; under PlacZ) This work
pAZIL-pBU6P-5 pBU6 digested with PvuII into pAZIL predigested with SmaI (second orientation) This work
pAZIL-pBU6B-2 pBU6 digested with BglII into pAZIL predigested with BamHI (first orientation; under PlacZ) This work
pAZIL-pBU6B-4 pBU6 digested with BglII into pAZIL predigested with BamHI (second orientation) This work
pBluescriptT/A-PlliBU PCR-amplified fragment carrying PlliBU cloned into pBluescriptT/A ∗ This work
pNZ8150-h1 hyp1 cloned into pNZ8150 under PlliBU ∗ This work
pNZ8150-h2 hyp2 cloned into pNZ8150 under PlliBU ∗ This work
pNZ8150-h1+h2 hyp1 and hyp2 cloned into pNZ8150 under PlliBU ∗ This work
pNZ8150-h3 hyp3 cloned into pNZ8150 under Phyp3∗ This work
pNZ8150-
h3+mobC+relM+rnaY
hyp3, mobC, relM and rnaY cloned into pNZ8150 under Phyp3 ∗ This work
pAZIL-EEB pAZIL-SB partially digested with EcoRI (without fragment of 382 bp which containing PlliBU and
part of the lliBU gene)
This work
pNZ8150-EEB XbaI fragment from pAZIL-EEB carrying whole lactolisterin BU cluster with non-functional lliBU gene This work
pAZIL-S-h1 PCR-amplified fragment carrying PlliBU, lliBU, abcT and hyp1 cloned into pAZIL ∗ This work
pAZIL-S-h1+h2-TT2 PCR-amplified fragment carrying PlliBU, lliBU, abcT, hyp1 and hyp2 without TT2 cloned into pAZIL ∗ This work
pAZIL-S-
h1+h2+1/2TT2
PCR-amplified fragment carrying PlliBU, lliBU, abcT, hyp1 and hyp2 with 1/2 TT2 cloned into pAZIL ∗ This work
pAZIL-S-h1+h2+TT2 PCR-amplified fragment carrying PlliBU, lliBU, abcT, hyp1 and hyp2 with TT2 cloned into pAZIL ∗ This work
pNZ8150-PlliBU-lacZ1 PlliBU cloned into pNZ8150-lacZ1 ∗ This work
pNZ8150-PlcnB-lacZ1 PlcnB cloned into pNZ8150-lacZ1 ∗ This work
Derivatives
MG7284/pBU6 MG7284 transformed with plasmid pBU6 (producer of lactolisterin BU) Lozo et al., 2017
MG7284/pAZIL-SP MG7284 transformed with pAZIL-SP This work
MG7284/pAZIL-SB MG7284 transformed with pAZIL-SB This work
MG7284/pAZIL-SS MG7284 transformed with pAZIL-SS This work
MG7284/pAZIL-
pBU6P-1
MG7284 transformed with pAZIL-pBU6P-1 This work
MG7284/pAZIL-
pBU6P-5
MG7284 transformed with pAZIL-pBU6P-5 This work
MG7284/pAZIL-
pBU6B-2
MG7284 transformed with pAZIL-pBU6B-2 This work
MG7284/pAZIL-
pBU6B-4
MG7284 transformed with pAZIL-pBU6B-4 This work
(Continued)
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TABLE 1 | Continued
Strains, plasmids, and derivatives Relevant characteristics Source
MG7284/pNZ8150-h1 MG7284 transformed with pNZ8150-h1 This work
MG7284/pAZIL-SS+pNZ8150-h1 MG7284/pAZIL-SS transformed with pNZ8150-h1 This work
MG7284/pNZ8150-h2 MG7284 transformed with pNZ8150-h2 This work
MG7284/pAZIL-SS+pNZ8150-h2 MG7284/pAZIL-SS transformed with pNZ8150-h2 This work
MG7284/pNZ8150-h1+h2 MG7284 transformed with pNZ8150-h1+h2 This work
MG7284/pAZIL-SS+pNZ8150-h1+h2 MG7284/pAZIL-SS transformed with pNZ8150-h1+h2 This work
MG7284/pNZ8150-h3 MG7284 transformed with pNZ8150-h3 This work
MG7284/pAZIL-SS+pNZ8150-h3 MG7284/pAZIL-SS transformed with pNZ8150-h3 This work
MG7284/pAZIL-SB+pNZ8150-h3 MG7284/pAZIL-SB transformed with pNZ8150-h3 This work
MG7284/pAZIL-SP+pNZ8150-h3 MG7284/pAZIL-SP transformed with pNZ8150-h3 This work
MG7284/pNZ8150-h3+mobC+relM+rnaY MG7284 transformed with pNZ8150-h3+mobC+relM+rnaY This work
MG7284/pAZIL-SS+pNZ8150-h3+mobC+relM+rnaY MG7284/pAZIL-SS transformed with pNZ8150-h3+mobC+relM+rnaY This work
MG7284/pAZIL-SB+pNZ8150-h3+mobC+relM+rnaY MG7284/pAZIL-SB transformed with pNZ8150-h3+mobC+relM+rnaY This work
MG7284/pNZ8150-EEB MG7284 transformed with pNZ8150-EEB This work
MG7284/pAZIL-SS+ pNZ8150-EEB MG7284/pAZIL-SS transformed with pNZ8150-EEB This work
MG7284/pAZIL-S-h1+h2-TT2 MG7284 transformed with pAZIL-S-h1+h2-TT2 This work
MG7284/pAZIL-S-h1+h2+1/2TT2 MG7284 transformed with pAZIL-S-h1+h2+1/2TT2 This work
MG7284/pAZIL-S-h1+h2+TT2 MG7284 transformed with pAZIL-S-h1+h2+TT2 This work
MG7284/pNZ8150-lacZ1 MG7284 transformed with pNZ8150-lacZ1 Vukotic et al., 2015
MG7284/pNZ8150-PlliBU-lacZ1 MG7284 transformed with pNZ8150-PlliBU-lacZ1 This work
MG7284/pNZ8150-PlcnB-lacZ1 MG7284 transformed with pNZ8150-PlcnB-lacZ1 This work
Ampr, resistance to ampicillin; Bacr, bacteriocin resistant; Cmr, resistance to chloramphenicol; Emr, resistance to erythromycin; Fusr, fusaric acid resistant; Lac−, lactose
utilization negative; Prt−, proteinase negative; Spcr, resistance to spectinomycin; ∗ for details, see the Section “Construction of Derivatives.”
All strains carrying constructs were stored in growth medium
containing 15% glycerol (Sigma Chemie GmbH, Deisenhofen,
Germany) at−80◦C.
DNA Manipulations
For plasmid isolation from E. coli a GeneJET Plasmid Miniprep
kit was used according to the manufacturer’s recommendations
(Thermo Fisher Scientific, Waltham, MA, United States).
Plasmids from lactococci were isolated by a modification of
the method described by O’Sullivan and Klaenhammer (1993).
Digestion with restriction enzymes was conducted according to
the supplier’s instructions (Thermo Fisher Scientific, Waltham,
MA, United States). The DNA fragments from agarose gels
were purified using QIAqick Gel extraction kit as described
by the manufacturer (Qiagen, Hilden, Germany). DNA was
ligated with T4 DNA ligase according to the manufacturer’s
recommendations (Agilent Technologies, United States).
PlatinumTM Taq DNA Polymerase High Fidelity (Thermo
Fisher Scientific, Waltham, MA, United States) was used
to amplify DNA fragments using a GeneAmp PCR System
2700 thermal cycler (Applied Biosystems, Foster City,
CA, United States). The PCR programs consisted of initial
denaturation (5 min at 96◦C), 30 cycles of denaturation (30 s at
96◦C), annealing (30 s at the appropriate temperature (Table 2)
and polymerization (2 min, 1 min or 30 s at 68◦C; depending
on the length of the amplified fragment), and an additional
extension step of 5 min at 68◦C. Sets of specific primers used
in this study are listed in Table 2. PCR products were purified
with a Thermo Scientific PCR Purification Kit according to the
manufacturer’s protocol (Thermo Fisher Scientific, Waltham,
MA, United States). For cloning PCR products a pBluescriptT/A
(Uzelac et al., 2015) or pAZIL vector were used.
Construction of Derivatives
The SacI/PvuII fragment from pBU6, containing the lactolisterin
BU operon (lliBU, abcT, hyp1 and hyp2), hyp3 and part of
mobC was cloned into pAZIL vector predigested with SacI/SmaI
restriction enzymes giving construct pAZIL-SP (Figure 1B and
Table 1). The fragment SacI/BglII from pBU6, containing just the
lactolisterin BU operon (lliBU, abcT, hyp1 and hyp2) was cloned
into pAZIL vector predigested with SacI/BamHI restriction
enzymes giving construct pAZIL-SB (Figure 1B and Table 1).
The SacI/ScaI fragment from pBU6, containing lliBU and abcT
was cloned into pAZIL vector predigested with SacI/SmaI
restriction enzymes giving construct pAZIL-SS (Figure 1B and
Table 1). In addition, (i) PvuII fragment from pBU6 (containing
whole pBU6 plasmid; PvuII restriction site cut of the start of
mobC) was cloned into pAZIL vector predigested with SmaI
restriction enzyme. Obtained constructs were named pAZIL-
pBU6P-1 and pAZIL-pBU6P-5 (both possible orientations)
(Figure 1B and Table 1); (ii) BglII fragment from pBU6
(containing whole pBU6 plasmid; BglII restriction site is within
the intergenic region of the hyp2 and hyp3 genes) was cloned
into pAZIL vector predigested with BamHI restriction enzyme.
Obtained constructs, were named pAZIL-pBU6B-2 and pAZIL-
pBU6B-4 (both possible orientations) (Figure 1B and Table 1).
MG7284 was transformed with each of the constructs and the
obtained derivatives were used as bacteriocin producers in the
agar well diffusion assay.
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TABLE 2 | Primers used in this study.
Primer name Sequence (5′ to 3′) Product size (bp) Temperature of annealing Reference
PBU1-4-Fw GGACTAAAAACAAGTAAC 136 42◦C This work
PBU1-4-Rev CATATGTAAGAGTACCTCC
lliBU-Fw ATGTGGGGTAGAATTCTTGG 134 51◦C This work
lliBU-Rev CATTCCAAGCTTATATTTTAACCCC
lliBU-Fw ATGTGGGGTAGAATTCTTGG 830 48◦C This work
abcT-Rev CAAATAATTCACGCTCC
lliBU-Fw ATGTGGGGTAGAATTCTTGG 1,486 44◦C This work
hyp1-Rev GAGTATCTACTTTTCAAG
lliBU-Fw ATGTGGGGTAGAATTCTTGG 2,004 54◦C This work
middle_the_loop_hyp2-Rev TGGCGGAAATATGTCCC
abcT-Fw CACAATTACCCAGAATTC 663 44◦C This work
abcT-Rev CAAATAATTCACGCTCC
abcT-Fw CACAATTACCCAGAATTC 1,319 44◦C This work
hyp1-Rev GAGTATCTACTTTTCAAG
abcT-Fw CACAATTACCCAGAATTC 1,837 48◦C This work
middle_the_loop_hyp2-Rev TGGCGGAAATATGTCCC
hyp1PstI-Fw CTGCAGTATTGGAGCGTGAATTATTTG 677 53◦C This work
hyp1XbaI-Rev TCTAGATTTCAAGTCCTATACCTTCG
hyp2PstI-Fw CTGCAGGTTAGAAACGAAGGTATAGG 570 55◦C This work
hyp2XbaI-Rev TCTAGATTTGGCGGAAATATGTCC
hyp3BglII-Fw GGAGATCTACAAAACTTAAGG 615 48◦C This work
hyp3-Rev GTAAGAATCCTCCTCTCG
hyp3BglII-Fw GGAGATCTACAAAACTTAAGG 2,585 48◦C This work
ribonucleaseY-Rev GGCTCACTCAGTTCGGTCAGGG
SacI_before_prom-Fw GAGTGGTTAGGAGCTCC 1,860 41◦C This work
hyp1-Rev GAGTATCTACTTTTCAAG
SacI_before_prom-Fw GAGTGGTTAGGAGCTCC 2,366 44◦C This work
before_the_loop- hyp2-Rev GTCCCAATTAATACTAGC
SacI_before_prom-Fw GAGTGGTTAGGAGCTCC 2,378 51◦C This work
middle_the_loop_hyp2-Rev TGGCGGAAATATGTCCC
SacI_before_prom-Fw GAGTGGTTAGGAGCTCC 2,434 52◦C This work
after_the_loop- hyp2-Rev CGCTTCCCCGAACCCCCG
LcnB-Fw AGTTATTAACATTTGTTAACG 77 38◦C This work
LcnB-Rev CATAATAATCTCCTTATTTTTATAAATC
Introduced restriction sites are indicated by underlined sequences.
The lactolisterin BU promoter, PlliBU, was amplified by
PCR using primers PBU1-4-Fw and PBU1-4-Rev where pBU6
was used as a template (Table 2). The obtained fragment
was cloned into pBluescriptT/A vector giving a construct
named pBluescriptT/A-PlliBU (Table 1). The hyp1 gene was
amplified from pBU6 using the hyp1PstI-Fw and hyp1XbaI-
Rev primers (Table 2) and cloned into pBluescriptT/A vector
(giving the construct pBluescriptT/A-h1). The XbaI fragment
was transferred, downstream of the PlliBU promoter, into the
pBluescriptT/A-PlliBU predigested with XbaI restriction enzyme,
giving the construct pBluescriptT/A-PlliBU-h1. The SacI/EcoRV
fragment from pBluescriptT/A-PlliBU-h1 was transferred into
pNZ8150 vector predigested with SacI/ScaI restriction enzymes
giving the construct pNZ8150-h1 (Figure 1D and Table 1). The
hyp2 gene was amplified from pBU6 plasmid using the hyp2PstI-
Fw and hyp2XbaI-Rev primers (Table 2) and cloned into
pBluescriptT/A vector giving the construct pBluescriptT/A-h2.
The XbaI fragment was transferred, downstream of the PlliBU
promoter, into the pBluescriptT/A-PlliBU predigested with XbaI
restriction enzyme, giving the construct pBluescriptT/A-PlliBU-
h2. The SacI/EcoRV fragment from pBluescriptT/A-PlliBU-h2
was transferred into pNZ8150 vector predigested with SacI/ScaI
restriction enzymes giving the construct pNZ8150-h2 (Figure 1D
and Table 1). A fragment containing the hyp1 and hyp2 genes
was amplified from pBU6 plasmid using the hyp1PstI-Fw and
hyp2XbaI-Rev primers (Table 2) and cloned into pBluescriptT/A
vector giving the construct pBluescriptT/A-h1+h2. The XbaI
fragment was transferred, downstream of the PlliBU promoter,
into the pBluescriptT/A-PlliBU predigested with XbaI restriction
enzyme, giving the construct pBluescriptT/A-PlliBU-h1+h2. The
SacI/EcoRV fragment from pBluescriptT/A-PlliBU-h1+h2 was
transferred into pNZ8150 vector predigested with SacI/ScaI
restriction enzymes giving the construct pNZ8150-h1+h2
(Figure 1D and Table 1). The hyp3 gene (with its promoter –
Phyp3) was amplified by PCR using primers hyp3BglII-Fw
and hyp3-Rev where pBU6 was used as a template (Table 2)
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FIGURE 1 | Schematic representation of the construction of appropriate constructs. (A,F) Linear gene map of the pBU6 plasmid carrying the lactolisterin BU cluster;
(B–E) the scheme of construction of clones used for analysis of influence of different genes/regions on the expression of the lliBU gene. Relevant restriction sites are
indicated. The size and orientation of predicted ORFs are indicated by arrows. +/–, presence/absence of Trans (transformants); Bac, bacteriocin activity; Imm,
expressed limited immunity.
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and cloned into pBluescriptT/A vector, giving the construct
pBluescriptT/A-h3. The fragment from pBluescriptT/A-
h3 was transferred into pNZ8150 as PstI/XbaI giving the
construct pNZ8150-h3 (Table 1). Fragment containing the
hyp3, mobC, relM and rnaY genes was amplified by PCR
using primers hyp3BglII-Fw and rnaY-Rev where pBU6 was
used as a template (Table 2) and cloned into pBluescriptT/A
vector, giving the construct pBluescriptT/A-h3mobCrelMrnaY.
The fragment from pBluescriptT/A-h3mobCrelMrnaY was
transferred into pNZ8150 as PstI/XbaI fragment giving the
construct pNZ8150-h3+mobC+relM+rnaY (Table 1). MG7284
and MG7284/pAZIL-SS were transformed with each of the
constructs (pNZ8150-h1, pNZ8150-h2, pNZ8150-h1+h2,
pNZ8150-h3 and pNZ8150-h3+mobC+relM+rnaY) and
the obtained derivatives (listed in Table 1) were used as
bacteriocin producers in the agar well diffusion assay. MG7284
and MG7284/pAZIL-SB were transformed with the following
constructs (pNZ8150-h3 and pNZ8150-h3+mobC+relM+rnaY)
and the obtained derivatives (listed in Table 1) were used
as bacteriocin producers in the agar well diffusion assay.
MG7284/pAZIL-SP was transformed with pNZ8150-h3 and the
obtained derivative (Table 1) was used for further experiments.
The construct pAZIL-SB was partially digested with EcoRI
to remove a fragment of 382 bp (without PlliBU and first part
of the lliBU gene) giving the construct pAZIL-EEB. In order to
obtain pNZ8150-EEB, XbaI fragment from pAZIL-EEB (carrying
all lactolisterin BU operon with non-functional lliBU gene) was
recloned into pNZ8150 vector. MG7284 and MG7284/pAZIL-
SS were transformed with pNZ8150-EEB and the obtained
derivatives (Table 1) were used for further experiments.
A section of the operon from the SacI restriction site
(upstream of PlliBU) to the end of hyp1 gene was amplified by
PCR using primers SacI_before_prom-Fw and hyp1-Rev where
pBU6 was used as a template (Table 2) and cloned into pAZIL
vector (predigested with SmaI restriction enzyme), giving the
construct pAZIL-S-h1 (Figure 1C and Table 1). The constructs
pAZIL-S-h1+h2-TT2, pAZIL-S-h1+h2+1/2TT2 and pAZIL-
S-h1+h2+TT2 (Figure 1C and Table 1) were constructed as
described above using the appropriate primers (SacI_before_
prom-Fw/before_the_loop-hyp2-Rev, SacI_before_prom-Fw/mi
ddle_the_loop_hyp2-Rev and SacI_before_prom-Fw/after_the_
loop-hyp2-Rev, respectively) (Table 2). MG7284 was
transformed with each of the following constructs (pAZIL-
S-h1, pAZIL-S-h1+h2-TT2, pAZIL-S-h1+h2+1/2TT2 and
pAZIL-S-h1+h2+TT2) and the obtained derivatives (listed in
Table 1) were used as bacteriocin producers in the agar well
diffusion assay.
For analysis of the PlliBU promoter activity, PlliBU was
fused to lacZ1 gene in pNZ8150-lacZ1 vector. The PlliBU
promoter transcriptional fusion was constructed as follows;
PCR amplified fragments (primers are listed in Table 2) of
promoters PlliBU and PlcnB (promoter of lcnB gene used
as a control) were first cloned to pBluescriptT/A giving
constructs (pBluescriptT/A-PlliBU and pBluescriptT/A-PlcnB)
that were recloned as EcoRI-BamHI fragments to pNZ8150-lacZ1
(Table 1). The constructs, designated pNZ8150-PlliBU-lacZ1
and pNZ8150-PlcnB-lacZ1, were used for further experiments.
MG7284 was transformed with constructs pNZ8150-PlliBU-
lacZ1 and pNZ8150-PlcnB-lacZ1 separately, resulting in the
strains MG7284/pNZ8150-PlliBU-lacZ1 and MG7284/pNZ8150-
PlcnB-lacZ1. The resulting transformants were screened on solid
GM17 medium supplemented with chloramphenicol and X-gal.
DNA Sequencing and Sequence Analysis
Cloned fragments of all relevant constructs were sequenced by
Macrogen Sequencing Service (Macrogen Europe, Amsterdam,
Netherlands). The DNA Strider 1.4f7 program was used for
sequence analysis and ORF prediction.
Transformation of E. coli and L. lactis
subsp. cremoris MG7284
Standard heat-shock transformation was used for plasmid
transformation of E. coli competent cells (Hanahan, 1983).
L. lactis subsp. cremoris MG7284 was transformed with plasmid
constructs using a method described by Holo and Nes (1989) with
modifications. To obtain competent cells, the overnight culture
was diluted 100-fold in GM17 medium supplemented with 1%
glycine. After growth at 30◦C to an optical density at 600 nm
OD600 = 0.6 to 1.0, the cells were harvested by centrifugation at
room temperature at 5,000 × g. Following two washes in sterile
MilliQ water, the cells were suspended in 1/100 culture volume of
sterile MilliQ water. Aliquots (200 µl) of cells were mixed with 5–
10 µl of DNA dissolved in 10 mM Tris-hydrochloride (pH 7.5),
kept for 5 min at room temperature and then transferred to an
electroporation cuvette (2-mm electrode gap) and exposed to a
single electrical pulse. The pulse was delivered by a Gene Pulser
Eporator (Eppendorf, Hamburg, Germany) set at 25 µF and
normally at 2.0 kV. Immediately following the discharge 800 µl of
GM17 medium was added to suspensions. After regeneration for
2 h at 30◦C appropriate dilutions were spread on selective GM17
plates. Transformants were visible after 1 or 2 days of incubation
at 30◦C.
For clonal confirmation, pulse-field gel electrophoresis
(PFGE) was performed, as described previously by Kojic et al.
(2006).
Bacteriocin Activity Assay
For detection of bacteriocin activity, an agar-well diffusion assay
was performed as described previously by Kojic et al. (1991). For
testing the level of sensitivity to lactolisterin BU spot on the lawn
assay was used; double serial dilutions of purified lactolisterin
BU were spotted (5 µl) on the surface of the top agar inoculated
with each indicator strain. After 24 h of incubation at 30◦C plates
were examined for the presence of inhibition zones. A clear zone
of inhibition was taken as evidence of bacteriocin production.
For monitoring of time dependent production of bacteriocin by
different constructs all cultures were started with 1% inoculum
from overnight culture and activity of cell free supernatant was
tested after different time intervals.
Antimicrobial activity of cytoplasmic fraction was tested
in the following way: cells from 50 ml of overnight cultures
of bacteriocin producers (BGBU1-4 and MG7284/pAZIL-SB),
MG7284/pAZIL-SS and MG7284/pAZIL as negative control were
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harvested by centrifugation (10 min 5,000 × g), washed with
10 ml of PP buffer (0.5 M sucrose, 40 mM NH4-acetate, 10 mM
Mg-acetate, pH 7), treated with lysozyme (4 mg/ml in PP buffer)
30 min at 37◦C to obtain protoplasts. Protoplasts were gently
washed with PP buffer and diluted to obtain equal number of
cells. 1 ml of each sample was sonicated on ice for different time
period (20, 40, and 60 s) with intervals of 10 s per every 20 s
of treatment, to disrupt membrane. Cell debris was removed by
centrifugation (5 min 20,000 × g) and supernatant containing
cytoplasmic proteins was used in bacteriocin activity assay. Also
cell debris was resuspended in PP buffer and used as negative
control in bacteriocin activity assay.




β-Galactosidase activity was determined essentially as described
by Miller (1972) with the modification introduced by Uzelac
et al. (2015). The resulting derivative MG7284/pNZ8150-PlliBU-
lacZ1 and appropriate controls (MG7284/pNZ8150-PlcnB-lacZ1
and MG7284/pNZ8150-lacZ1) were analyzed with three separate
bacterial cultures in two independent experiments.
RT-PCR
Total mRNA was isolated from Lactococcus lactis subsp. lactis
BGBU1-4 at late logarithmic phase of growth using RNeasy
Mini Kit as described by the manufacturer (Qiagen, Hilden,
Germany). First strand cDNA synthesis with reverse transcriptase
was carried out as previously published by Uzelac et al. (2015).
The obtained cDNA was subsequently amplified by PCR using
appropriate pairs of primers (Table 2). The size of the obtained
PCR products was checked on a 1% agarose gel. Reproducibility
of obtained PCR products was confirmed in two independent
experiments.
RESULTS AND DISCUSSION
Lactolisterin BU production is plasmid encoded. In a previous
study, it was reported that Lactococcus lactis subsp. lactis BGBU1-
4 contains a plasmid, pBU6, carrying the structural lactolisterin
BU operon (Lozo et al., 2017). Based on comparisons with known
bacteriocin clusters, it was hypothesized that the lactolisterin BU
bacteriocin operon was organized into a four gene operon-like
structure consisting of (lliBU) the structural gene; (abcT) an ABC
transporter; and hyp1 and hyp2 genes to which the exact function
has not been attributed.
Comparative Analysis of Aureocin
A53-Like Clusters
Since lactolisterin BU showed the highest identity with
bacteriocins belonging to aureocin A53-like group (Lozo et al.,
2017), the possibility of a common origin was considered. To
determine the similarity of the organization of gene clusters
among aureocin A53-bacteriocins, lactolisterin BU operon was
compared with the three most similar aureocin A53-like
bacteriocin clusters: BHT-B bacteriocin from Streptococcus ratti
(GenBank: DQ145753.1), lacticin Z (GenBank: AB740019.1) and
lacticin Q (GenBank: AB712393.1) from Lactococcus lactis QU
5. It was found that the lactolisterin BU operon has a unique
organization that is distinct from the other aureocin A53-like
clusters (Figure 2). Bearing in mind that the aureocin A53-like
bacteriocin clusters do not show similarity, it can be assumed that
the cluster does not have a common origin. Thus, comparative
analysis with known aureocin A53-like clusters, did not help with
defining/predicting the exact function of hypothetical genes of
the lactolisterin BU cluster.
In silico Analysis of Genes in Lactolisterin BU Cluster
Downstream of the lactolisterin BU (lliBU) structural gene
are located an abcT gene encoding an ABC transporter ATP-
binding protein (domain architecture ID 11438412) and three
undefined hyp1, hyp2, and hyp3 genes, upstream of the mobC
gene, predicted to be involved in plasmid mobilization. In silico
analyses of these three hypothetical genes revealed that hyp1 is
predicted to encode a putative sugar ABC transporter permease
of 212 amino acid residues, but that hyp2 and hyp3 encode
proteins of 169 and 92 amino acids that share low level similarity
with uncharacterized proteins from LAB.
TMpred program prediction1 analysis of those three proteins
revealed the presence of transmembrane helices (Hyp1 = 6;
Hyp2 = 5 and Hyp3 = 2), indicating a cytoplasmic membrane
location for these proteins. In addition, it was found that all three
proteins have high pI values (Hyp1 = 10.52; Hyp2 = 9.77; and
Hyp3 = 11.05) and are rich in the amino acid leucine (20.5; 11.8;
and 15.5%, respectively).
In the lactolisterin BU cluster, two genes were predicted
to encode possible transporter/enzymes involved in sugar
catabolism, indicating that the lactolisterin BU peptide
determinant was somehow introduced upstream of a
sugar-related cluster and uses these proteins for its own
transport.
The absence or existence of small intergenic regions between
the genes of lactolisterin BU operon indicated the synthesis of a
single polycistronic RNA (the intergenic region between the lliBU
and abcT genes is 64 nucleotides; the abcT and hyp1 genes are
overlapped within 8 nucleotides; the intergenic region between
the hyp1 and hyp2 genes is only 3 nucleotides).
In silico analysis of the upstream region of lactolisterin
BU operon using the program Bacterial Promoter Prediction2
revealed the presence of five putative promoter structures
of which (TGAATATTTGCAATTTTTATATTAAATT) had the
highest score (1) and, thus the greatest likelihood of being active.
Analysis to detect the presence of transcriptional
terminators (TT) using3 revealed the presence of two apparent
transcriptional terminators in the lactolisterin BU operon:
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FIGURE 2 | Comparative analysis of aureocin A53-like clusters. (A) Schematic presentation of different aureocin A53-like bacteriocins gene clusters. (B) Predicted
3D peptide structures for different aureocin A53-like bacteriocins using Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2).
AGATTATATTTTAACC) and second a TT2 after the hyp2
gene at the end of operon (TTTCCGCCAAAAAAAGTAA
GCTATTCGCTTACTTTTTTTGGCGGAAA). The presence
of two transcription terminators in the lactolisterin BU operon
also pointed to the possibility that the first TT1 was introduced
together with the bacteriocin structural gene during insertion
into the sugar operon. We hypothesize that it was later modified
in order to provide a precise regulation of expression by
transcriptional attenuation.
Upstream of the lliBU, abcT, hyp1 and hyp2 at a variable
distance from the ATG translation start codon non-perfect
ribosomal binding sequences (RBSs) were detected (Table 3).
These RBS could be involved in translational regulation of
expression of each gene in the cluster.
Transcriptional Analysis of the
Lactolisterin BU Operon
In order to test if all genes (lliBU, abcT, hyp1, and hyp2) for
lactolisterin BU activity form an operon (transcribed as one
polycistronic mRNA), their expression was investigated by RT-
PCR using one forward primer from the lliBU gene and different
reverse primers positioned in the lliBU, abcT, hyp1 or hyp2
TABLE 3 | Position and sequence of RBS upstream of genes in lactolisterin BU
operon.
Gene Distance from ATG Sequence Consensus




genes. Due to the presence of a strong transcriptional terminator
immediately after the lliBU gene, an additional forward primer
from the abcT gene was designed and used for transcriptional
analysis. The results of RT-PCR analysis unambiguously showed
that all genes of the lactolisterin BU cluster were transcribed as
a single polycistronic mRNA (Figure 3). This was in line with
the previously characterized bacteriocin cluster for enterocin AS-
48 that is expressed by two polycistronic mRNA in coordinate
expression (Diaz et al., 2003).
Considering that production of lactolisterin BU in the strain
L. lactis subsp. lactis BGBU1-4 is balanced at low level since
higher production of bacteriocin cause the death of the producer
(Lozo et al., 2017), we wanted to determine the level of expression
at the transcriptional level through the construction of the
promoter PlliBU-lacZ fusion and the analysis of the activity. The
promoter PlcnB of the lactococcin B gene was used as a positive
control. Results of β-galactosidase activity of transcriptional
fusions revealed that promoter PlliBU had activity comparable
to promoter PlcnB (the difference in activity between the
MG7284/pNZ8150-PlcnB-lacZ1 and MG7284/pNZ8150-PlliBU-
lacZ1 did not have statistical significance; 183± 21: 169± 26 MU,
respectively). This result indicates that regulation of expression
was more likely to be at the translational level.
Cloning of Lactolisterin BU Operon in the pAZIL
Vector
Lactolisterin BU is encoded by a gene cluster located on
the smallest plasmid in strain BGBU1-4, pBU6 of 6.2 kb
(Figure 1A). To characterize a minimal bacteriocin cluster,
different fragments of pBU6 plasmid were cloned in a pAZIL
shuttle vector (Figure 1B and Table 1). The smallest fragment
providing bacteriocin activity in heterologous strain MG7284
was the 2,552 bp SacI-BglII fragment containing the lliBU, abcT,
Frontiers in Microbiology | www.frontiersin.org 9 November 2018 | Volume 9 | Article 2774
fmicb-09-02774 November 13, 2018 Time: 17:45 # 10
Miljkovic et al. Function of Lactolisterin BU Gene Cluster
FIGURE 3 | Transcriptional analysis of the lactolisterin BU operon. Amplicons
obtained after RT-PCR using (A) lliBU-Fw and (I) lliBU-Rev; (II) abcT-Rev; (III)
accBU-Rev; (IV) immBU-Rev; (B) abcT-Fw and (V) abcT-Rev; (VI) accBU-Rev;
(VII) immBU-Rev primers; (a) schematic presentation of primer positions and
length of PCR products in lactolisterin BU operon; (b) electrophoresis of
obtained PCR products on 1% agarose gel; L – GeneRuler DNA Ladder Mix
0.1–10 kb (Thermo Fisher Scientific); 1 – cDNA of BGBU1-4; 2 – RT-PCR
negative control (without reverse transcriptase); 3 – total DNA of BGBU1-4;
4 – PCR negative control (without DNA of BGBU1-4).
hyp1 and hyp2 genes (Figures 1B, 4). It was interesting that
the construct pAZIL-SB (pAZIL vector containing SacI-BglII
fragment) exhibited stronger antimicrobial activity than the wild
type strain and transformants of MG7284 with pBU6 plasmid.
Construct pAZIL-SP (pAZIL vector containing the SacI-PvuII
fragment) showed even better antimicrobial activity (higher
zone of inhibition; Figure 4) than a transformant with pAZIL-
SB construct indicating the influence of other genes/structures
on bacteriocin activity. Plasmid construct pAZIL-SS (pAZIL
containing SacI–ScaI fragment of 1,284 bp) carrying only the
lliBU and abcT genes did not provide antimicrobial activity,
indicating that additional gene(s) were needed for bacteriocin
production. In order to prove this conclusion we performed
bacteriocin activity assay with cytoplasmic fraction of different
strains: bacteriocin producers (BGBU1-4 and MG7284/pAZIL-
SB), MG7284/pAZIL-SS and MG7284/pAZIL as negative control.
Very low bacteriocin activity (1 mm of inhibition zone) was
obtained only with strains that already produce bacteriocin
in supernatant (BGBU1-4 and MG7284/pAZIL-SB), which was
originated from residual bacteriocin molecules that were not
exported (no bacteriocin activity was obtained with cell debris)
strongly indicated that no bacteriocin synthesis occurs inside of
the cells carrying pAZIL-SS construct, although the structural
bacteriocin gene is present and an active promoter. According
to both in silico analysis (all four genes are transcribed as
polycistronic mRNA) and subcloning results, it can be concluded
that the operon is located on the SacI-BglII fragment and consists
of four structural genes: lliBU, abcT, hyp1 and hyp2. In addition,
the time-dependent production of bacteriocin, that was noted
in the parental BGBU1-4 strain (Lozo et al., 2017), was also
tested in derivatives MG7284/pAZIL-SP and MG7284/pAZIL-
SB. It was observed that derivative MG7284/pAZIL-SB retained
time-dependent production of bacteriocin, like the parental
strain (although bacteriocin production was higher), while
MG7284/pAZIL-SP lost time-dependent production of the
bacteriocin (Figure 4A). In addition to the role of specific genes,
the influence of the orientation of the fragment in the vector
on bacteriocin expression was observed (Figure 4B) indicating
that some (promoter or other) sequences from the vector could
boost the expression. Thus, it was noticed that depending on
the orientation of the same fragment (BglII linearized plasmid
pBU6), expression of bacteriocin could drastically differ.
The hyp1 Gene Encodes an Accessory Protein
In order to determine the role of the hyp1 gene, we made
additional constructs (Figures 1B–E and Table 1). The most
important construct for determining the function of the hyp1
gene was pAZIL-S-h1 (containing a cloned PCR fragment
carrying PlliBU, lliBU, abcT, and hyp1 genes). Transformants
were successfully obtained in E. coli, but no transformants were
obtained in MG7284 after three independent attempts. In control
transformations with the same competent cells, but with other
constructs (pAZIL-SS, pAZIL-SB, and pAZIL-SP), we obtained
between 6× 104 and 2× 105/µg of plasmid DNA. By combining
the obtained results with respect to the activity of subclones, it
can be concluded that the hyp1 gene encoded for the accessory
protein and was designed as the accL gene (Figure 1F). The
combined evidence is as follows (i) the pAZIL-SS construct did
not provide antimicrobial activity because it lacked a key protein
for delivery of bacteriocin, an accessory protein, (ii) construct
pAZIL-S-h1 contained all genes necessary for synthesis and
transport of bacteriocin and provided transformants to produce
active bacteriocin that killed themselves due to the absence of
the immunity protein. These results explain why in the first case
transformants that lacked bacteriocin production capacity were
generated and in the second, we were not able to get them at all.
The location of an accessory protein downstream from the gene
for ABC transporter was previously confirmed for the bacteriocin
BacSJ (Kojic et al., 2010) and many other class II bacteriocins (Nes
et al., 1996) and that it is essential for export of bacteriocins in
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FIGURE 4 | Antimicrobial activity of constructed derivatives on Lactococcus lactis subsp. cremoris MG7284. (A) Time dependent antimicrobial activity of
MG7284/pAZIL 1 – SP, 2 –SB, 3 – BGBU1-4, 4 – MG7284. (B) Dependence of cluster orientation cloned into pAZIL vector on antimicrobial activity: MG7284/pAZIL
1 – pBU6P-1, 2 – pBU6P-5, 3 – pBU6B-2, 4 – pBU6B-4, 5 – SP, 6 – SB. (C) Bacteriocin activity of lactolisterin BU cluster expressed in trans (a) MG7284/pAZIL 1 –
SP, 2 – SB, MG7284/3 – pNZ8150-h1, 4 – pAZIL-SS+pNZ8150-h1, 5 – pNZ8150-h2, 6 – pAZIL-SS+pNZ8150-h2, 7 – pNZ8150-h1+h2, 8 –
pAZIL-SS+pNZ8150-h1+h2, 9 – pNZ8150-EEB, 10 – pAZIL-SS+pNZ8150-EEB, 11 – pNZ8150-h3, 12 – pAZIL-SS+pNZ8150-h3, 13 – pAZIL-SS, 14 – MG7284;
(b) MG7284/pAZIL 1 – SP, 2 – SP+pNZ8150-h3, 3 – SB, 4 – SB+pNZ8150-h3.
addition to the ABC transporter. In lactolisterin BU and BHT-
B operons accessory protein resembles permease enzymes which
can contribute to streamlining its role in bacteriocin transport
and interaction with ABC transporter.
The hyp2 Gene Is Responsible for Immunity to
Lactolisterin BU
A construct containing the hyp2 gene was the only one that had
the ability to synthesize and increase resistance to lactolisterin
BU. In addition, for construct pAZIL-S-h1, which contains the
operon without the hyp2 gene, it was not possible to obtain any
transformants due to the apparent absence of immunity.
To determine if the hyp2 gene product (alone) can provide
immunity to lactolisterin BU, this gene was amplified and cloned
under the control of the PlliBU promoter, transferred to pNZ8150
vector and expressed in MG7284. The transformants carrying
this construct were exposed to different concentrations (500, 250,
125, 62.5, 31.2, 15.6, 7.8, and 3.9 µg/ml) of purified lactolisterin
BU and it was found that all of them were as sensitive as the
sensitive strain MG7284 (Table 4). To further investigate the
possible role of the hyp2 gene product in providing immunity
to lactolisterin BU all constructs were exposed to different
concentrations (500, 250, 125, 62.5, 31.2, 15.6, 7.8, and 3.9 µg/ml)
of purified lactolisterin BU in a spot on the lawn bacteriocin
assay. It was observed that constructs containing a functional
hyp2 gene showed approximately four times higher resistance
to bacteriocin then “sensitive strains”- i.e., the same or even
higher than the parental strain-producer of lactolisterin BU
(Figure 5 and Table 4). Since the function of the hyp2 gene
was determined to be to provide immunity to lactolisterin BU,
the gene was renamed immL (Figure 1F). Notably, a limited
level of protection against its own synthesized antimicrobial
molecule was noted for aureocin A53-like bacteriocins previously
(Iwatani et al., 2007). Most likely it is the limiting factor
for bacteriocin production, which must be well balanced in
order not to kill itself. It could be assumed that low level of
immunity to lactolisterin BU is result of balanced translational
regulation or still ongoing transition of sugar to bacteriocin
operon.
The Transcription Terminator TT2 Did
Not Influence the Expression of
Lactolisterin BU in Lactococci
It has been documented that transcription terminators can be
involved in regulation of gene expression by transcriptional
attenuation or impacting on the stability of mRNA originating
from bacteriocin operons (Uzelac et al., 2015). Different
constructs were made to determine the possible involvement of
TT2 in the expression of lactolisterin BU (Figure 1C). It was
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FIGURE 5 | Sensitivity of representative strains and derivatives to different concentrations of purified lactolisterin BU in spot on the lawn bacteriocin assay.
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TABLE 4 | Sensitivity of all analyzed derivatives to different concentrations of purified lactolisterin BU in spot on the lawn bacteriocin assay.
Name of derivative Concentration of purified lactolisterin BU (µg/ml)
125 62.5 31.2 15.6 7.8 3.9
BGBU1-4 + + + − − −
BGMN1-596 + + + + − −
MG7284 + + + + − −
MG7284/pBU6 + + + − − −
MG7284/pAZIL-SP + + +/− − − −
MG7284/pAZIL-SB + + +/− − − −
MG7284/pAZIL-SS + + + + +/− −
MG7284/pAZIL-pBU6P-1 + + + − − −
MG7284/pAZIL-pBU6P-5 + + + − − −
MG7284/pAZIL-pBU6B-2 + + + − − −
MG7284/pAZIL-pBU6B-4 + + + − − −
MG7284/pNZ8150-h1 + + + + − −
MG7284/pAZIL-SS+pNZ8150-
h1
+ + + + − −
MG7284/pNZ8150-h2 + + + + − −
MG7284/pAZIL-SS+pNZ8150-
h2
+ + + + − −
MG7284/pNZ8150-h1+h2 + + + + − −
MG7284/pAZIL-SS+pNZ8150-
h1+h2
+ + + + − −
MG7284/pAZIL-SB+pNZ8150-
h3
+ + +/− − − −
MG7284/pAZIL-SB+pNZ8150-
h3+mobC+relM+rnaY
+ + +/− − − −
MG7284/pNZ8150-EEB + + + + − −
MG7284/pAZIL-SS+pNZ8150-
EEB
+ + + + − −
MG7284/pAZIL-S-h1+h2-TT2 + + +/− − − −
MG7284/pAZIL-S-
h1+h2+1/2TT2
+ + +/− − − −
MG7284/pAZIL-S-h1+h2+TT2 + + +/− − − −
found that constructs without TT2 expressed the same level of
bacteriocin (the same size of the zone of inhibition), indicating
that TT2 was not involved in additional regulation of lactolisterin
BU expression.
Product of the hyp3 Gene Modulates
Expression of Lactolisterin BU
The possible involvement of the hyp3 gene in expression
of lactolisterin BU was also analyzed (Figure 1E). During
subcloning of the pBU6 plasmid, it was noticed that construct
pAZIL-SP provided a larger zone of inhibition than pAZIL-SB
(that contains the perceived complete lactolisterin gene cluster),
despite the growth of bacteriocin producer MG7284/pAZIL-SP
being lower. In addition, when the hyp3 gene was subcloned
into the pNZ8150 vector and co-expressed with pAZIL-SB
in MG7284, it provided the same level of lactolisterin BU
production as MG7284/pAZIL-SP (Figure 4Cb). The hyp3 gene
did not belong to lactolisterin BU operon, but may somehow
modulate expression or transport of lactolisterin BU, possibly due
its membrane location.
The Lactolisterin BU Operon Expressed
in trans Does Not Provide Bacteriocin
Activity
Subcloning experiments with the pBU6 plasmid showed that the
lactolisterin BU gene cluster consists of four genes (lliBU, abcT,
accL and immL) clustered as one transcriptional unit. To test
the possibility of in trans expression by different combinations
of lactolisterin BU genes, the following experiments were
completed: the lactolisterin BU operon was split and cloned
into two compatible vectors with different selection markers
(pAZIL and pNZ8150) carrying different parts (genes) of the
cluster (lliBU + abcT, hyp1 and hyp2; lliBU and abcT +
hyp1 and hyp2; lliBU and abcT + hyp1; lliBU and abcT +
hyp2) (Figures 1E, 4Ca). Transcription of the first part of
the operon was driven by the natural promoter PlliBU, while
the second part was also constructed to be transcribed under
the same promoter. Results of bacteriocin testing showed that
combinations of in trans co-expressed lactolisterin BU genes were
not able to restore bacteriocin activity, indicating an obligate in cis
gene constellation. This indicates that bacteriocin expression
Frontiers in Microbiology | www.frontiersin.org 13 November 2018 | Volume 9 | Article 2774
fmicb-09-02774 November 13, 2018 Time: 17:45 # 14
Miljkovic et al. Function of Lactolisterin BU Gene Cluster
is controlled by a translational coupling mechanism, providing
an optimal ratio of proteins within the operon to obtain enough
bacteriocin molecules for combating competitors, but not so
much as to kill itself due to limited immunity.
The results of this study highlight that sophisticated
mechanisms of regulation were involved in expression of genes
within the lactolisterin BU cluster, which require further study.
Elucidation of regulatory mechanisms involved in the expression
of lactolisterin BU could help in making constructs for the
overexpression of bacteriocins and/or other proteins of interest.
CONCLUSION
The lactolisterin BU cluster consists of four genes (lliBU, abcT,
accL, and immL) clustered as one transcriptional unit under
the PlliBU promoter. Gene product functions were determined
to be: lliBU – the bacteriocin structural gene, abcT – the ABC
transporter, accL – the transporter accessory protein and immL
– an immunity protein which provides limited protection. PlliBU
promoter activity was determined to be as strong as that of PlcnB,
indicating that expression is predominantly regulated at the
translational level. The absence of activity when the gene cluster
was divided and expressed in trans indicates that bacteriocin
expression is controlled to provide an optimum ratio of protein
expression levels within the operon. The operon functions in cis
constellation of genes ensuring the optimal amount of each
product for the cell most probably by a translational coupling
mechanism. In addition, it was found that the presence of
the hypothetical gene/protein 3, located downstream of the
lactolisterin BU operon (possesses its own promoter) has a
positive effect on the bacteriocin expression.
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